Short answer
MeiraGTx Holdings plc (MGTX) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $5M (up 1074.1% year over year) with net income of −$51M.
Q3 2026 key financials · XBRL
- Revenue
- $5M
- +1074.1% YoY · −98.5% QoQ
- Net income
- −$51M
- −1.4% YoY · −131.9% QoQ
- Operating margin
- -1036.1%
- EPS (diluted)
- −$0.62
- +0.0% YoY · −133.2% QoQ
Source: XBRL data from the MeiraGTx Holdings plc (MGTX) Q3 2026 10-Q on SEC EDGAR. USD.
MeiraGTx Holdings plc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $4.8M, up $0.4M YoY from $4.4M, driven by Lilly and Reogen services
- Quarterly net loss $51.3M vs $50.5M; operating loss $49.9M vs $46.1M
- Best program: AAV-hAQP1 R&D expense $6.2M, up from $2.0M; manufacturing highest at $16.7M
- Cash, cash equivalents and restricted cash $186.8M; operating cash use $45.3M through nine months
- Outlook: funding expected into second half of 2028; bota-vec EMA submission planned December 2026 and FDA BLA first quarter 2027
Risk Factors
- Newly added regulatory risk: EU pharmaceutical reforms adopted September 2026 could change data protection, exclusivity, access obligations and review procedures
- Most material financial update: Royalty Note Purchase Agreement adds up to $375 million secured obligations, with maturity on June 30, 2036
- Compliance risk: GDPR violations could trigger fines up to €20 million or 4% of worldwide annual turnover
- Near-term operational risk: Limited plasmid suppliers and manufacturing capacity could delay clinical trials or commercialization
- Liquidity risk: $186.8 million in cash, equivalents and restricted cash estimated sufficient into the second half of 2028 with assumptions- Newly added regulatory risk: EU pharmaceutical reforms adopted September 2026 could change data protection, exclusivity, access obligations and review procedures
- Most material financial update: Royalty Note Purchase Agreement adds up to $375 million secured obligations, with maturity on June 30, 2036
- Compliance risk: GDPR violations could trigger fines up to €20 million or 4% of worldwide annual turnover
- Near-term operational risk: Limited plasmid suppliers and manufacturing capacity could delay clinical trials or commercialization
- Liquidity risk: $186.8 million in cash, equivalents and restricted cash estimated sufficient into the second half of 2028 with assumptions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MeiraGTx Holdings plc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.